<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="753">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338360</url>
  </required_header>
  <id_info>
    <org_study_id>20-003312</org_study_id>
    <nct_id>NCT04338360</nct_id>
  </id_info>
  <brief_title>Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19</brief_title>
  <official_title>Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      This expanded access program will provide access to investigational convalescent plasma for
      patients in acute care facilities infected with SARS-CoV-2 who have severe or
      life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of
      progression to severe or life-threatening disease.
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>COVID19</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 convalescent plasma</intervention_name>
    <description>COVID-19 convalescent plasma</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years

          -  Laboratory confirmed diagnosis of infection with SARS-CoV-2

          -  Admitted to an acute care facility for the treatment of COVID-19 complications

          -  Severe or life threatening COVID-19, or judged by the treating provider to be at high
             risk of progression to severe or life-threatening disease

          -  Informed consent provided by the patient or healthcare proxy

        Severe COVID-19 is defined by one or more of the following:

          -  dyspnea

          -  respiratory frequency ≥ 30/min

          -  blood oxygen saturation ≤ 93%

          -  partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt; 300

          -  lung infiltrates &gt; 50% within 24 to 48 hours

        Life-threatening COVID-19 is defined as one or more of the following:

          -  respiratory failure

          -  septic shock

          -  multiple organ dysfunction or failure

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michael Joyner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Albert Lea</name>
      <address>
        <city>Albert Lea</city>
        <state>Minnesota</state>
        <zip>56007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Austin</name>
      <address>
        <city>Austin</city>
        <state>Minnesota</state>
        <zip>55912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Cannon Falls</name>
      <address>
        <city>Cannon Falls</city>
        <state>Minnesota</state>
        <zip>55009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Lake City</name>
      <address>
        <city>Lake City</city>
        <state>Minnesota</state>
        <zip>55041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Mankato</name>
      <address>
        <city>Mankato</city>
        <state>Minnesota</state>
        <zip>56001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Owatonna</name>
      <address>
        <city>Owatonna</city>
        <state>Minnesota</state>
        <zip>55060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Red Wing</name>
      <address>
        <city>Red Wing</city>
        <state>Minnesota</state>
        <zip>55066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System - Eau Claire</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System - Franciscan Healthcare</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <link>
    <url>http://www.USCOVIDplasma.org</url>
    <description>Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael J. Joyner, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

